“Letter to the Editor: Paclitaxel‐Coated Balloons for Femoropopliteal Artery Disease Treatment in French Patients: A Longitudinal Observational Study”

We read with great interest the article by Gouëffic et al. [1] titled “Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease Treatment in French Patients: A Longitudinal Observational Study.” This study provides valuable real-world evidence on the long-term effectiveness of drug-coated balloons (DCBs) for femoropopliteal artery disease. The authors are commended for using national health data to generate meaningful clinical insights. Such work bridges the gap between trials and real-world practice. However, several additional limitations warrant attention. First, the study assessed only one DCB (IN.PACT Admiral, Medtronic) without comparison to other devices. Variations in drug dose, excipient, and release kinetics among DCBs affect outcomes, limiting generalizability and potentially biasing results toward a single device's performance. For instance, Thieme et al. [2] compared outcomes of the Lutonix DCB and showed that performance and safety differ across devices based on coating and dosage, highlighting the need for device-specific analysis. Second, the study was fully funded by Medtronic, the manufacturer of the IN.PACT Admiral DCB, and key data analysis was conducted by Medtronic. This introduces the risk of sponsor bias, particularly in data interpretation and outcome framing, potentially favoring positive results or minimizing adverse findings. For instance, Lundh et al. [3] analyzed multiple medical fields and found that industry-sponsored studies were more likely to report favorable efficacy results and conclusions compared with nonindustry-funded research. Third, the SNDS database lacks data on smoking intensity, duration of diabetes, renal function levels, and degree of limb ischemia, all of which significantly impact outcomes. Unmeasured confounders may have led to residual confounding, falsely attributing outcomes to DCB use rather than to patient comorbidity severity or risk factor control. For instance, Secemsky et al. [4] reported that claims-based data lacked key lesion and procedural details, such as length and severity, which led to residual confounding even after statistical adjustment. Fourth, the study lacked lesion-specific details (length, calcification, occlusion type) and did not stratify by Rutherford or TASC II classes, which are critical predictors of PAD outcomes. Failure to adjust for anatomical or clinical complexity may cause confounding by indication, misattributing poor outcomes to device effect rather than disease severity. For instance, Reijnen et al. [5] showed that lesion length and CLTI status independently predict mortality and reintervention after DCB treatment, underscoring the need for detailed lesion stratification. Future studies should compare different DCB devices using propensity-matched national registries to assess safety and effectiveness. Independent oversight and blinded evaluation are needed to reduce sponsor bias. Linking clinical registries with electronic health records will add essential clinical and anatomical details. Incorporating imaging databases will allow lesion-specific, risk-adjusted outcome analyses. In conclusion, while Gouëffic et al. [1] have provided meaningful real-world insights into the use of DCBs for femoropopliteal artery disease, methodological and data limitations restrict the broader applicability of their findings. Addressing device diversity, funding bias, unmeasured confounding, and lesion-specific variability in future studies will strengthen the evidence base and ensure more accurate and generalizable conclusions about DCB safety and effectiveness in routine clinical practice. The authors have nothing to report. Artificial Intelligence Generated Content: Artificial intelligence (AI) tools, specifically OpenAI's ChatGPT (GPT-4), were used to assist in the drafting and editing of this manuscript. These tools were employed solely to support language refinement, grammar correction, and structural clarity. No AI-generated content was used to replace or simulate original intellectual contributions, data interpretation, critical analysis, or conceptual development. All substantive content reflects the authors' own work and interpretation. The authors have reviewed and verified all AI-assisted text to ensure accuracy and integrity in accordance with the journal's authorship and ethical standards. The authors have nothing to report. The authors declare no conflicts of interest. The authors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and if relevant, registered) have been explained. Data sharing does not apply to this article as no data sets were generated during the current study; all data were sourced from published literature.